Archer-Daniels-Midland Company

▲ Bull Case

• ◆Mid-cycle margin recovery plus $400–500M annual cost savings realization drives EBITDA toward $4.5B and EPS to ~$6.50–7.50 by FY2027, implying $97–112/share (25–45% upside) at normalized 15x multiple.
• ◆Legal resolution at $150–250M consent decree removes governance discount and re-rates stock by 1–2 EV/EBITDA turns; 10x EV/EBITDA on $4.0B EBITDA implies $70–90/share upside.
• ◆Biofuel policy tailwind (EPA SAF pathway approval using corn ethanol) provides non-consensus Carbohydrate Solutions upside of $100–200M OP; ADM's #1 US ethanol position becomes significant unmodeled option.

▼ Bear Case

• ◆Goodwill impairment cascade of $1.5–2.0B pre-tax is structurally probable: Nutrition segment earns ~$300–400M OP on ~$4.8B goodwill (~4% asset return, below WACC); triggers 1–2 quarter EPS hole of -$3–4/share; bear case falls to $35–55.
• ◆Structural competitive shift from Bunge-Viterra permanently compresses US crushing margins: if Bunge captures 3–5% US crushing share, ADM's AS&O OP declines by $200–400M structurally—irreversible loss.
• ◆DOJ criminal indictment escalation triggers credit downgrade, executive exodus, asset sales; stock trades toward distressed levels ($25–45) during uncertainty period.

“Central debate: 'Recovery trade at trough multiples vs. structural value trap.' Recovery camp (12 Buys) sees Dividend Aristocrat at trough EV/EBITDA of ~20x pricing only partial recovery; 11% normalized FCF yield is exceptional. Value trap camp (3 Sells, 21 Holds) cites ROIC below WACC in 4 of 5 recent years, $5B+ value-destructive Nutrition acquisitions, and permanent structural compression from Bunge-Viterra. Tiebreaker: Q3–Q4 2026 earnings. If AS&O segment OP exceeds $1,000M/quarter, recovery case wins; below $750M/quarter strengthens value trap thesis.”

• ◆Q2/Q3 2026 earnings confirm crush-spread trajectory: if AS&O OP exceeds $650M for two consecutive quarters, recovery is real and EPS upgrade cycle begins.
• ◆DOJ/SEC investigation resolution (consent decree, NPA, or settlement): any resolution removes uncertainty discount; re-rates stock 1–2 EV/EBITDA turns; historical precedent suggests $200–500M penalty is absorbable.
• ◆CFO Patolawala's first guidance upgrade: external CFO (hired Oct 2024) has credibility on line; upgrade restores management credibility destroyed by FY2024 miss; +$0.70–1.00 EPS run-rate impact.
• ◆Net debt below $7.0B (ND/EBITDA <2.5x) triggers buyback restart announcement: significant sentiment catalyst for 82% institutional owner base.
• ◆Nutrition segment EBIT recovery above $450M: validates acquisitions were temporarily underperforming not permanently destructive; unlocks specialty-ingredient multiple re-rating.
• ◆Biofuel policy clarity (EPA SAF pathway finalization by H2 2026): corn ethanol feedstock approval could deliver +$300–500M CS OP, free call option not in consensus.

• ◆Goodwill impairment ($1.5–2.0B): medium probability, medium impact, non-cash but confidence-destroying; confirms Nutrition acquisition was permanently value-destructive.
• ◆DOJ criminal escalation: low probability (15–20%) but high impact (credit downgrade, CEO turnover, operational overhang); key tail risk for long holders.
• ◆Bunge-Viterra structural margin compression: high probability of being structural and irreversible; most pernicious risk because it happens quietly without announcement.
• ◆US-China trade escalation (soybeans targeted): medium probability (30% over 2 years), high impact; could reduce AS&O OP by $300–500M; elevated given current May 2026 tariff environment.
• ◆Working capital FCF normalization disappointment: high probability; FY2025's $4.2B FCF reverts to $1.5–2.0B in FY2026; anchored investors could sell off 10–15% on normalization.